Small Noncoding RNA Profiling Across Cellular and Biofluid Compartments and Their Implications for Multiple Sclerosis Immunopathology
Overview
Authors
Affiliations
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease affecting the central nervous system (CNS). Small non-coding RNAs (sncRNAs) and, in particular, microRNAs (miRNAs) have frequently been associated with MS. Here, we performed a comprehensive analysis of all classes of sncRNAs in matching samples of peripheral blood mononuclear cells (PBMCs), plasma, cerebrospinal fluid (CSF) cells, and cell-free CSF from relapsing-remitting (RRMS, = 12 in relapse and = 11 in remission) patients, secondary progressive (SPMS, = 6) MS patients, and noninflammatory and inflammatory neurological disease controls (NINDC, = 11; INDC, = 5). We show widespread changes in miRNAs and sncRNA-derived fragments of small nuclear, nucleolar, and transfer RNAs. In CSF cells, 133 out of 133 and 115 out of 117 differentially expressed sncRNAs were increased in RRMS relapse compared to remission and RRMS compared to NINDC, respectively. In contrast, 65 out of 67 differentially expressed PBMC sncRNAs were decreased in RRMS compared to NINDC. The striking contrast between the periphery and CNS suggests that sncRNA-mediated mechanisms, including alternative splicing, RNA degradation, and mRNA translation, regulate the transcriptome of pathogenic cells primarily in the CNS target organ.
Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing.
Tan I, Modderman R, Stachurska A, Almeida R, de Vries R, Heersema D Brain Commun. 2024; 6(4):fcae209.
PMID: 38978729 PMC: 11229703. DOI: 10.1093/braincomms/fcae209.
Small RNAs: An expanding world with therapeutic promises.
Gou L, Zhu Q, Liu M Fundam Res. 2024; 3(5):676-682.
PMID: 38933305 PMC: 11197668. DOI: 10.1016/j.fmre.2023.03.003.
Palacio P, Pleet M, Reategui E, Magana S J Neuroimmunol. 2023; 377:578064.
PMID: 36934525 PMC: 10124134. DOI: 10.1016/j.jneuroim.2023.578064.
Women in the field of multiple sclerosis: How they contributed to paradigm shifts.
Barateiro A, Barros C, Pinto M, Ribeiro A, Alberro A, Fernandes A Front Mol Neurosci. 2023; 16:1087745.
PMID: 36818652 PMC: 9937661. DOI: 10.3389/fnmol.2023.1087745.
Chiricosta L, Blando S, DAngiolini S, Gugliandolo A, Mazzon E Int J Mol Sci. 2023; 24(2).
PMID: 36674968 PMC: 9862618. DOI: 10.3390/ijms24021448.